TYVASO DPI IS NOW APPROVED

The first and only FDA-approved treatment for PH-ILD1

TYVASO SHIFTS
THE OUTLOOK FOR PH-ILD1

TYVASO and TYVASO DPI are inhaled prostacyclin mimetics indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.1,2

The study with TYVASO establishing effectiveness predominately included patients with etiologies of1,2:

  • Idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF)
  • Combined pulmonary fibrosis and emphysema (CPFE) (25%)
  • WHO Group 3 connective tissue disease (22%)
Five dollar co-pay icon

Eligible patients
could pay as little
as a $5 co-pay
for each prescription

Patient support icon

Learn about support
services for patients

Get in contact with a United Therapeutics Representative

TYVASO DPI®
THE PROVEN EFFICACY OF TYVASO® IN THE PALM OF YOUR HAND1,2

TYVASO DPI Inhalation Powder is a simple-to-use, inhaled prostacyclin therapy that delivers the trusted safety and benefits of TYVASO.1,2

Get the details about TYVASO DPI.

DPI=dry powder inhaler.

References: 1. TYVASO DPI [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2022. 2. Spikes LA, Bajwa AA, Burger CD, et al. BREEZE: open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI in patients with pulmonary arterial hypertension. Pulm Circ. 2022;12:e12063. doi:10.1002/pul2.12063.

This referral form has recently been revised to include TYVASO DPI™ (treprostinil) Inhalation Powder, a new dry powder inhaler option for your patients.

Currently, the 48 mcg (112 ct) and 64 mcg (112 ct) Maintenance Kits (28-day supply) are available for ordering. These strengths correspond with 8-10 breaths and 11-12 breaths with the TYVASO nebulizer, respectively. The remaining Maintenance Kits and Titration Kits will be available soon.

To learn more about TYVASO DPI and Kit availability, please reach out to your local United Therapeutics Cardiopulmonary Specialist.

Okay